Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stanley Riddell
Fred Hutchinson Cancer Research Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Juno Therapeutics
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
The goal of this project is to develop adoptive T cell therapy for patients with acute lymphoblastic leukemia who undergo allogeneic stem cell transplant from an HLA matched related donor. The preclinical and initial clinical studies that were performed on this project provided part of the rationale to form Juno, and it is likely that subsequent Phase 2 studies will be funded by Juno. The value of Dr. Riddell’s financial interests in Juno could be impacted depending on the outcome of this research.
Targeted therapy of B cell malignances with CAR-T cells of defined composition
Immunotherapy is emerging as a new and effective modality for cancer therapy. One of the most promising approaches is to engineer the patient's T cells to express a synthetic receptor that instructs the T cell to seek out and eliminate cancer cells. The studies in this application focus on translating this approach into a reproducible and safe therapy for patients with leukemia and lymphoma.
Filed on July 13, 2015.
Tell us what you know about Stanley Riddell's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Stanley Riddell filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | >$600,000 |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | $60,000 - $79,999 |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | $60,000 - $79,999 |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | Value cannot be readily determined |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | Value cannot be readily determined |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.